Shang Mao, Chang Chunxiao, Pei Yanqing, Guan Yin, Chang Jin, Li HuiHui
School of Medicine and Life Sciences, University of Jinan Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 250117.
J Cancer. 2018 Nov 24;9(24):4627-4634. doi: 10.7150/jca.28458. eCollection 2018.
As a specific subtype of breast cancer, Triple-negative breast cancer (TNBC) is associated with worse prognosis and higher tumor aggressiveness than HER2-amplified or hormone receptor positive breast cancers. Circulating tumor DNA (ctDNA), as a non-invasive "liquid biopsy", is an emerging original blood-based biomarker for early breast cancer diagnosis, monitoring treatment response, and determining prognosis. In TNBC patients, ctDNA has an inherent tendency to characterize tumor heterogeneity and metastasis-specific mutations providing a key alternative to tumor tissue profiling. Several studies have already demonstrated the potential of ctDNA in TNBC patients from early to advanced stages of the disease including diagnosis, therapy decisions and assessment of prognosis. This review provides a critical brief summary of the evidence that gives credence to the utility of ctDNA as a biomarker for its role into clinical management in TNBC.
作为乳腺癌的一种特定亚型，三阴性乳腺癌（TNBC）与HER2扩增型或激素受体阳性乳腺癌相比，预后更差，肿瘤侵袭性更高。循环肿瘤DNA（ctDNA）作为一种非侵入性的“液体活检”，是一种新兴的基于血液的生物标志物，可用于早期乳腺癌诊断、监测治疗反应和判断预后。在TNBC患者中，ctDNA具有表征肿瘤异质性和转移特异性突变的内在倾向，为肿瘤组织分析提供了关键替代方法。多项研究已经证明了ctDNA在TNBC患者疾病早期到晚期阶段的潜力，包括诊断、治疗决策和预后评估。本综述对支持ctDNA作为生物标志物在TNBC临床管理中作用的证据进行了重要简要总结。
